Glaxo J&J Combination May Control HIV With Monthly Injections

Monthly injections with HIV therapies from GlaxoSmithKline Plc and Johnson & Johnson sustained levels of the drugs in blood that should control the virus, according to a study that suggests the shots may one day provide a safer, more convenient treatment option to daily pills.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.